Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Revenues Soar to Record-Breaking $100B in 2022 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Pfizer Revenues Soar to Record-Breaking $100B in 2022

Comirnaty and Paxlovid rake in $56.7 billion in 2022 while sales of these COVID products are expected to decline as much as 60% in 2023.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
4Q Revenues: $24.3 billion (+2%)
4Q Earnings: $5.0 billion (+47%)
YTD Revenues: $100.3 billion (+23%)
YTD Earnings: $31.4 billion (+43%)
Comments: Growth was primarily driven by Covid-19 products: Comirnaty sales were $11.3 billion in the quarter, down 9% and $37.8 billion for the year, up 3%. Paxlovid sales were $1.8 billion in the quarter and $18.9 billion for the year. Excluding contributions from Paxlovid and Comirnaty, revenues in the quarter grew $571 million, or 5%.
 
Primary Care sales were $17.3 billion in the quarter, up 7% and $73.0 billion for the year, up 40%.

Specialty Care sales were down 11% to $3.6 billion in the quarter and down 9% to $13.8 billion for the year.

Oncology sales were down 7% to $3.0 billion in the quarter and down 2% to $12.1 billion for the year.

Prevnar family sales in the quarter were $1.7 billion, up 33% and $6.3 billion for the year, up 20%. In the U.S., sales were up 79%, driven primarily by demand and favorable timing of Centers for Disease Control and Prevention (CDC) purchasing of the pediatric indication.  
 
Revenues from recently acquired products, Nurtec ODT/Vydura and Oxbryta, contributed $211 million and $73 million in global revenues, respectively.
 
Vyndaqel family sales were up 21% to $680 million in the quarter and $2.4 billion for the year.
 
Eliquis sales in the quarter were $1.5 billion, down 1% and $6.5 billion for the year, up 9%.
 
Enbrel sales were down 21% in the quarter to $236 million and down 15% for the year to $1.0 billion.
 
Xeljanz sales were down 32% to $493 million in the quarter and down 27% to $1.8 billion for the year. 
 
Sutent sales were down 56% in the quarter to $60 million and down 48% to $347 million for the year, primarily driven by lower demand in Europe following loss of exclusivity in January 2022.
 
Pfizer CentreOne revenues were $368 million in the quarter, down 4% and $1.3 billion for the year, down 22%. Pfizer CentreOne includes revenues from Pfizer’s contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech. Revenues related to Comirnaty manufacturing activities totaled $80 million and $188 million for the fourth quarter and full-year 2022, respectively, and $46 million and $320 million for the fourth-quarter and full-year 2021, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters